Cite
HARVARD Citation
Maakaron, J. et al. (n.d.). A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas. European journal of cancer. pp. S28-. [Online].